编号：2025-06 | | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 □业绩说明会 | | 活动类别 | □新闻发布会 ☑路演活动 | | | □现场参观 □其他 | | | 1、中泰证券股份有限公司：陈鼎如、马梦泽 | | | 2、国寿安保基金管理有限公司：祁善斌 | | | 3、上海宝弘资产管理有限公司：赵鹏 | | | 4、华创证券有限责任公司：范益民、於尔东 | | | 5、天风证券股份有限公司上海证券自营分公司：王璐 | | | 6、上海古曲私募基金管理有限公司：朱一木 | | 参与单位 | 7、深圳望正资产管理有限公司：汪程程 | | 名称 | 8、国海证券股份有限公司：张钰莹、何钟书 | | | 9、野村东方国际证券有限公司资产管理部：唐建伟 | | | 10、上海加鹏资产管理有限公司：黄伟鑫 | | | 11、广东恒昇基金管理有限公司：罗煦娟 | | | 12、国弘天下資本集团有限公司：康超 | | | 13、上海左道投资管理有限公司：肖杰 | | | 14、浙江弘悦私募基金管理有限公司：聂磊 | | | 15、上海重鼎资产管理有限公司：张 ...

Group 1: Investor Relations Activities - The company participated in multiple roadshows and strategy meetings from May 7 to May 9, 2025, in Shanghai, Hangzhou, and Beijing [2][3] - Key participants included various securities firms and investment funds such as Huafu Securities, Vanguard Fund, and others [2][3] Group 2: Q1 2025 Performance Highlights - The EV·DTB superstructure business achieved sales of 6,000 units, a year-on-year increase of 11.6%, with revenue reaching 660 million CNY and contributing a gross profit of 20 million CNY [3][4] - In North America, the company sold 4,156 semi-trailers, generating revenue of 18 million USD, despite a declining market with a fifth consecutive quarter of decreased trailer registrations [4] Group 3: Strategic Developments - The company is focusing on enhancing its supply chain resilience in North America by increasing local procurement and establishing backup supplies in Thailand and Canada [4] - The development of the pure electric head-mounted train (EV-RT2.0) is underway, with market research and product testing already initiated [5][6] Group 4: Future Growth Opportunities - The company identifies significant growth opportunities in the unified national market and global southern markets, planning to leverage initiatives like the "Starlink Plan" and "Xiongqi Plan" to maximize value across the semi-trailer value chain [6] - The company aims to transform into a preferred partner for new energy heavy-duty truck chassis, focusing on innovation and strategic partnerships [6]

| | □特定对象调研 □分析师会议 | | --- | --- | | 投资者关系 | □媒体采访 业绩说明会 | | | □新闻发布会 □路演活动 | | 活动类别 | □现场参观 □电话会议 | | | □其他： （请文字说明其他活动内容） | | 参与单位名称及 | | | | 日科化学 2024 年度业绩说明会采用网络远程方式进行，面向全体投资者 | | 人员姓名 | | | 时间 2025 | 年 月 日 5 9 15:00-17:00 | | 地点 | 深圳证券交易所"互动易平台"http://irm.cninfo.com.cn"云访谈"栏目 | | | 主持人：日科化学 董事长：田志龙 | | 公司接待人员 | 财务总监：姜霖 | | 姓名 | 副经理兼董事会秘书：曹鸣 | | | 独立董事：朱鸿霄 | | | 1.高管您好，请问您如何看待行业未来的发展前景？谢谢。 | | | 答：投资者您好。首先，关于塑料和橡胶改性剂行业未来，我们认 | | | 为：1、木塑复合材料行业发展持续向好，带动 产品市场需求不断 ACR | | | 带来发 扩大；2、新兴领域带动电线电缆行业需求提升，为橡胶型 ...

证券代码：300214.SZ 证券简称：日科化学 山东日科化学股份有限公司投资者关系活动记录表 编号：2025-01 | 投资者关系活动 | □特定对象调研 分析师会议 | | --- | --- | | 类别 | □媒体采访 业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 □其他 | | 参与单位名称 | 华泰证券、上海敦颐资产、华泰资管、Pleiad Investment | | | Advisors Limited、粤港澳大湾区共同家园发展基金、九坤投 | | | 资、化雨频沾私募基金、混沌投资、趣时资管、孝庸私募、浙 | | | 商证券、景顺长城基金、人寿保险、兴业基金、农银汇理、创 | | | 新投资集团、Willing Capital Management Limited、君阳私 | | | 募、泰信基金、东吴基金、瀚伦投资、新华基金、华软新动力 | | | 私募、凯丰投资、龙航资管、昭图资管、泓澄资管、Pleiad | | | Investment Advisors Limited、光大理财、百川财富、SEQUOIA | | | CAPITAL LLP、太平资管、摩 ...

投资者关系活动记录表 证券代码：300452 证券简称：山河药辅 安徽山河药用辅料股份有限公司投资者关系活动记录表 编号：2025-002 | | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他（电话交流会） | | | 国融基金 彭双宇；TX CAPITAL (HK) LIMITEDHank Ren；中 | | | 邮证券 鲁春娥；国泰海通证券 甘坛焕 唐玉青 付子阳；首 | | | 创证券 王斌、刘琳；申万宏源证券 梁飚；爱建证券 章孝林； | | | 银河基金 方伟；福建辰盛资产 郑玉君；浦银安盛基金 龚剑 | | | 成；东方财富 何雪频；民生银行 唐谷军；冰河资产 刘春茂； | | | 荷荷（北京）私募基金 唐巍；民生证券 唐梦涵；中信证券 韩 | | | 世通；光大证券 曹聪聪；循远资产 田超平；天风证券刘一 | | 参与单位名称及人员姓名 | 伯；东方证券 王光宇；上海红象投资 胡玉阳；开源证券 阮 | | | 帅；信达医药 唐爱金；天弘基金 王政 ...

证券代码：301178 证券简称：天亿马 广东天亿马信息产业股份有限公司 | 具有竞争力的算力服务综合解决方案。 | | --- | | 截至报告期末，公司已获得在手订单约 8 亿元，为 2025 年业绩 | | 提升和改善打下坚实的基础。 | | 4、你们行业本期整体业绩怎么样？你们跟其他公司比如何？ | | 2024 年智慧城市行业市场需求放缓、竞争加剧。公司谨慎承接 | | 业务，继续巩固政务、教育、医疗等领域优势，进一步开拓了智慧 | | 轨道交通、智慧企业、智慧能源业务；同时，公司加速布局数据要 | | 素和算力服务领域。2025 年一季度财报，公司营收同比增长 21.95%， | | 净利润扭亏为盈，经营活动现金流同比改善超 79%，反映出运营管理 | | 的成效。 | | 5、贵公司在整个市场环境下行的情况下能否详细的阐述一下未来发 | | 展战略规划！ | | 2025 年，公司继续围绕"转型、提质"的战略总目标，紧抓"数 | | 字经济"发展机遇，坚持内生增长与外部并购相结合策略，不断增 | | 强自身实力和核心竞争力。 | | 在原有核心业务方面，我们巩固夯实"智慧政务、智慧教育、 | | ...

投资者关系活动记录表 编号：2025-001 投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 ☐其他（请文字说明其他活动内容） 参与单位名称及人员姓名 线上参与公司2024年度网上业绩说明会的全体投资者 时间 2025年05月09日 15:00-16:30 地点 价值在线（https://www.ir-online.cn/）网络互动 上市公司接待人员姓名 董事长 刘召贵 董事会秘书 肖廷良 财务总监 吴志进 独立董事 王刚 投资者关系活动主要内容 介绍 1.根据《上市规则》，公司被ST后若2024年继续亏损或审计意见 未改善将面临退市。管理层是否有明确的扭亏计划（如资产重组、债 务优化）？当前净资产如何？ 答:尊敬的投资者，您好！公司2025年第一季度处于盈利状态， 公司主营业务分析仪器行业持续经营稳定，管理层明确将聚焦主业， 逐步剥离PPP项目。2025年3月31日归属于上市公司股东净资产 128,051.39万元。 2.年报显示环境监测仪器业务营收同比下降28%，毛利率下滑至 行业低位。请分析核心产品竞争力流失原因，是否考虑战略转型或剥 离非 ...

Group 1: Business Strategy and Market Position - The company focuses on enhancing product quality while expanding its market share through acquisitions and partnerships with high-quality material technology firms [2][3] - Over 93% of the company's main revenue comes from domestic engineering machinery manufacturers, with only 7% from overseas sales [6] - The company is actively exploring opportunities in the new energy vehicle sector and will disclose relevant developments in due course [4] Group 2: Financial Performance and Projections - In 2024, the net increase in cash and cash equivalents was -92,718,573.88 CNY, a decrease of 277% year-on-year, primarily due to a significant asset restructuring [4] - The company anticipates potential fluctuations in performance due to macroeconomic conditions and industry cycles, while emphasizing the importance of material research and product quality [4][5] - A cash dividend is planned for the 2024 fiscal year, reflecting a strong capital reserve and retained earnings [6] Group 3: Product Development and Innovation - The company is developing perfluoroether rubber seals for semiconductor equipment, with ongoing testing and validation processes [5] - Current products have achieved domestic substitution in certain applications, such as excavators and oil and gas extraction equipment, competing with international brands [6] - There are plans to explore the humanoid robot market, although no current products are specifically designed for this sector [6][7]

Group 1: Financial Performance - The company's revenue for 2024 reached 98,355.45 million, a year-on-year increase of 10.42% [2] - Net profit attributable to shareholders was 1,365.17 million, up 119.02% year-on-year, with the parent company's net profit at 5,635.84 million, increasing by 838.39% [2] - In Q1 2025, revenue was 28,268.07 million, showing a growth of 36.23% year-on-year, while net profit rose to 1,453.85 million, up 26.13% [2] Group 2: Profitability and Margins - The gross margin for 2024 was 47.67%, an increase of 0.66 percentage points compared to 2023 [3] - The company plans to enhance gross margins through continuous improvement in production processes and cost reduction [3] Group 3: Product Performance - Sales revenue from contrast agents reached 58,804.95 million in 2024, a growth of 9.87% year-on-year [3] - Sales of antidiabetic products grew by 33.24% year-on-year, attributed to successful bidding and subsequent contracts [4] Group 4: Research and Development - R&D expenses for 2024 were 6,923.81 million, a decrease of 43.40% compared to the previous year, due to a more stable phase in R&D and improved efficiency [5] - The company has 12 projects under review and 23 new R&D projects initiated [5] Group 5: Subsidiary Developments - The acquisition of Tianyuan Pharmaceutical increased the number of traditional Chinese medicine products to 59, with a focus on promoting unique products [8] - The construction of the production base for Luzhibao Pharmaceutical is ongoing, with trial production expected to start within the year [7] Group 6: Investor Relations and Governance - The total number of shareholders decreased by 7.37% by the end of Q1 2025, indicating a shift towards attracting more quality investors [10] - The company emphasizes a stable and scientific dividend policy to ensure sustainable returns to shareholders [10] Group 7: Debt Management - The company has sufficient funds to repay the principal and interest of convertible bonds due next year, ensuring no repayment risk [11]

证券代码：002361 证券简称：神剑股份 安徽神剑新材料股份有限公司投资者关系活动记录表 编号：2025-002 | | 分析师会议 □特定对象调研 □ | | | --- | --- | --- | | 投资者关系活 | 媒体采访 √ 业绩说明会 | □ | | 动类别 | 新闻发布会 □ 路演活动 | □ | | | 现场参观 | □ | | | 其他 （请文字说明其他活动内容） | □ | | 参与单位名称 | 投资者网上提问 | | | 及人员姓名 | | | | 时间 | 年 月 日 5 9 (周五) 下午 15:00~17:00 | 2025 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 采用网络远程的方式召开业绩说明会 | | | | 1、董事长、总经理 刘志坚 | | | 上市公司接待 | 2、董事、常务副总、财务总监 吴昌国 | | | 人员姓名 | 3、运营总监兼董秘 李成玉 | | | | 4、独立董事 王申生 投资者提出的问题及公司回复情况 | | | | 公司就投资者在本次说明会中提出的问题进行了回复： 1、领导，您 ...